TransMedics Group TMDX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
TransMedics Group (TMDX) Core Market Data and Business Metrics
Latest Closing Price
$68.27Price-Earnings Ratio
73.41Total Outstanding Shares
33.66 Million SharesDividend
No dividendSIC Description
Electromedical & Electrotherapeutic ApparatusPrimary Exchange
NASDAQHeadquarters
200 Minuteman Road, Andover, MA, 01810
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,075,060 Shares | 8.88 | 3/14/2025 | 9,551,242 Shares |
| 1,682,984 Shares | 5.54 | 2/28/2025 | 9,330,007 Shares |
| 1,242,812 Shares | 8.66 | 2/14/2025 | 10,756,834 Shares |
| 1,798,031 Shares | 6.19 | 1/31/2025 | 11,129,933 Shares |
| 3,951,562 Shares | 2.28 | 1/15/2025 | 8,990,700 Shares |
| 1,307,474 Shares | 7 | 12/31/2024 | 9,153,451 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $-97.02 Million |
| Net Cash Flow, Continuing | $-97.46 Million |
| Net Cash Flow From Operating Activities | $37.44 Million |
| Exchange Gains/Losses | $443,000 |
| Net Cash Flow From Financing Activities | $22.61 Million |
| Net Cash Flow From Investing Activities, Continuing | $-157.51 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Costs And Expenses | $368.44 Million |
| Income/Loss From Continuing Operations Before Tax | $32.65 Million |
| Selling, General, and Administrative Expenses | $156.27 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Net Income/Loss Available To Common Stockholders, Basic | $32.64 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $32.67 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $29,000 |
| Comprehensive Income/Loss | $32.70 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $785.57 Million |
| Equity Attributable To Parent | $209.92 Million |
| Noncurrent Liabilities | $515.60 Million |
| Liabilities | $575.65 Million |
| Fixed Assets | $271.74 Million |
| Equity | $209.92 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||